Aegerion Says Lomitapide 78-Week Phase III Data Consistent With Earlier Results
(RTTNews) – Aegerion Pharmaceuticals Inc. (AEGR: News ) provided a clinical update on its lead investigational therapeutic, lomitapide. Aegerion reported that the 78-week data from its pivotal Phase III clinical trial are consistent with data previously reported at the 26- and 56-week time points. The Phase III study was a single-arm, open label trial, designed to evaluate the efficacy and long-term safety of lomitapide for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). The data demonstrate that the reduction in LDL-C cholesterol from baseline was maintained at 78-weeks. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, in clinical development as an oral, once-a-day therapeutic for HoFH. Click here to receive FREE breaking news email alerts for Aegerion Pharmaceuticals Inc. and others in your portfolio by RTT Staff Writer For comments and feedback: contact editorial@rttnews.com
Article source: http://www.rttnews.com/1793075/aegerion-says-lomitapide-78-week-phase-iii-data-consistent-with-earlier-results.aspx?type=qf
Filed Under Cholesterol News | Leave a Comment
Tagged With cholesterol news
Comments
Leave a Reply